The new Prolaris + AI test merges genomic data with digital pathology AI to assess prostate cancer risk. Myriad Genetics uses this multimodal approach to refine patient stratification. The tool provides clinicians with more precise prognostic data. This incremental update streamlines pathology workflows by automating visual analysis of tissue samples.